About this trial
This prospective observational study aims to assess the health-related quality of life (HRQoL) of 200 children (ages 5-16) with bronchial asthma, allergic rhinitis, or both, and their 200 parents, comparing 100 children receiving specific immunotherapy with 100 receiving routine treatment. Using EQ-5D-Y(EuroQol five dimensions questionnaire, youth version), disease-specific scales, and newly developed Chinese versions of EQ-5D-Y and EQ-HWB-S (EuroQol health and well-being questionnaire, short version), the study evaluates HRQoL changes over 1 and 2 years and explores the impact on caregiver burden and spillover effects. A control group of 100 healthy children and their parents will be included. Data collection involves baseline and follow-up surveys, clinical data from medical records, and statistical analyses to compare treatment effects and validate measurement tools.
Eligibility criteria
Qualifiers
Aged 5-16 years;
Diagnosed with bronchial asthma, allergic rhinitis, or both (persistent, duration ≥4 weeks) by a respiratory or allergy specialist;
Guardian has signed the informed consent form;
Able to understand and complete the questionnaire;
Disqualifiers
Poor compliance;
Already received specific immunotherapy at another hospital;
Unable to independently read and complete the questionnaire;
Lost to follow-up or discontinued treatment.
Trial design
Treatments tested in this trial
- Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
Treatment groups
Sponsors and collaborators
Wenjing Zhou
Lead sponsor
RenJi Hospital
Sponsor institution